M.D., Distinguished Research Fellow: Head, Cancer Immunology Discovery Biomarkers, Boehringer-Ingelheim Pharmaceuticals
Sid Kerkar is a Distinguished Research Fellow and Head of Boehringer Ingelheim’s Cancer Immunology Discovery Biomarker group. Dr. Kerkar completed post-doctoral research in tumor immunology in the surgery branch and clinical training in pathology at the National Cancer Institute, NIH under Dr. Steven A. Rosenberg and Dr. Nicholas P. Restifo. His research at NIH was recognized through several awards including the NCI Director’s Innovation Award, the NIH Center for Human Immunology Bench to Bedside Award, the Fellow’s Award for Research Excellence, the Presidential Travel Award, Society for Immunotherapy of Cancer and the NIH Clinical Center Leadership Award. His group is responsible for defining precision medicine biomarkers and harnessing biomarker driven research to identify targets and pathways of interest for BI’s global Cancer Immunology portfolio.
Immunotherapy Showcase: Boehringer-Ingelheim Pharmaceuticals
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer-Ingelheim.
Biomarker Research In Early Drug Discovery
Precision medicine requires a thorough understanding of the therapeutic target and mechanism of actions in human tissue. This presentation will describe discovery bi-omarker activities in Cancer Immunology at Boehringer-Ingelheim Pharmaceuticals.